HRP20050103B1 - N-aril supstituirani bifenilkarboksamidi kao inhibitori sekrecije apolipoproteina b - Google Patents

N-aril supstituirani bifenilkarboksamidi kao inhibitori sekrecije apolipoproteina b

Info

Publication number
HRP20050103B1
HRP20050103B1 HRP20050103AA HRP20050103A HRP20050103B1 HR P20050103 B1 HRP20050103 B1 HR P20050103B1 HR P20050103A A HRP20050103A A HR P20050103AA HR P20050103 A HRP20050103 A HR P20050103A HR P20050103 B1 HRP20050103 B1 HR P20050103B1
Authority
HR
Croatia
Prior art keywords
apolipoprotein
inhibitors
secretion
piperidine substituted
aryl piperidine
Prior art date
Application number
HRP20050103AA
Other languages
English (en)
Inventor
Lieven Meerpoel
Leo Jacobus Jozef Backx
Peter Walter Maria Roevens
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20050103A2 publication Critical patent/HRP20050103A2/xx
Publication of HRP20050103B1 publication Critical patent/HRP20050103B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4

Abstract

Metode za pripremu N-aril piperidin supstituiranih bifenilkarboksamidnih spojeva formule (I), metode za pripremu takvih spojeva, farmaceutske kompozicije koje uključuju navedene sastojke kao i upotreba istih kao lijek za tretman hiperlipidemije, pretilosti i dijabetesa tip II. Ovi spojevi djeluju kao inhibitori apolipoproteina B.
HRP20050103AA 2002-08-12 2005-02-01 N-aril supstituirani bifenilkarboksamidi kao inhibitori sekrecije apolipoproteina b HRP20050103B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078309 2002-08-12
PCT/EP2003/008694 WO2004017969A1 (en) 2002-08-12 2003-08-05 N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion

Publications (2)

Publication Number Publication Date
HRP20050103A2 HRP20050103A2 (en) 2006-09-30
HRP20050103B1 true HRP20050103B1 (hr) 2013-09-30

Family

ID=31896911

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050103AA HRP20050103B1 (hr) 2002-08-12 2005-02-01 N-aril supstituirani bifenilkarboksamidi kao inhibitori sekrecije apolipoproteina b

Country Status (32)

Country Link
US (2) US20060040989A1 (hr)
EP (1) EP1536796B1 (hr)
JP (1) JP4559856B2 (hr)
KR (1) KR101052204B1 (hr)
CN (3) CN101165053A (hr)
AR (1) AR040968A1 (hr)
AT (1) ATE385796T1 (hr)
AU (1) AU2003250215B2 (hr)
BR (1) BR0313377A (hr)
CA (1) CA2494208C (hr)
CY (1) CY1107945T1 (hr)
DE (1) DE60319097T2 (hr)
DK (1) DK1536796T3 (hr)
EA (1) EA008061B1 (hr)
EG (1) EG25699A (hr)
ES (1) ES2301873T3 (hr)
HK (1) HK1083451A1 (hr)
HR (1) HRP20050103B1 (hr)
IL (1) IL166795A (hr)
IS (1) IS2726B (hr)
MX (1) MXPA05001712A (hr)
MY (1) MY136632A (hr)
NO (1) NO329308B1 (hr)
NZ (1) NZ538680A (hr)
PA (1) PA8579901A1 (hr)
PL (1) PL212405B1 (hr)
PT (1) PT1536796E (hr)
SI (1) SI1536796T1 (hr)
TW (1) TWI342775B (hr)
UA (1) UA79300C2 (hr)
WO (1) WO2004017969A1 (hr)
ZA (1) ZA200501225B (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83510C2 (en) * 2003-12-09 2008-07-25 Янссен Фармацевтика Н.В. N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
FR2883000B1 (fr) * 2005-03-14 2007-06-01 Merck Sante Soc Par Actions Si Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EP1948629A1 (en) 2005-10-31 2008-07-30 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
CN102851291B (zh) * 2006-04-03 2016-03-09 斯特拉有限责任公司 包含抗微小rna反义寡核苷酸的药物组合物
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
CA2681406A1 (en) * 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
US8580756B2 (en) * 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
US20110054011A1 (en) * 2007-08-30 2011-03-03 Mccullagh Keith RNA Antagonist Compounds for the Modulation of FABP4/AP2
ES2360929T3 (es) * 2007-09-20 2011-06-10 Amgen Inc. Derivados del ácido 1-(4-(4-bencilbenzamido)-bencil)azetidin-3-carboxílico y compuestos relacionados como moduladores del receptor s1p para el tratamiento de trastornos inmunitarios.
ES2463665T3 (es) * 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
CA2717792A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
JP5773535B2 (ja) * 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
EP2456870A1 (en) 2009-07-21 2012-05-30 Santaris Pharma A/S Antisense oligomers targeting pcsk9
EP3591054A1 (en) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Antisense oligomers and conjugates targeting pcsk9
ES2826603T3 (es) 2014-06-16 2021-05-18 Johnson Matthey Plc Procesos para la preparación de compuestos de arilpiperazina alquilada y arilpiperidina alquilada que incluyen productos intermedios novedosos

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096327A1 (en) * 2000-06-01 2001-12-20 Glaxo Group Limited BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS
WO2001097810A2 (en) * 2000-06-01 2001-12-27 Glaxo Group Limited Use of therapeutic benzamide derivatives
WO2002020501A2 (en) * 2000-09-04 2002-03-14 Janssen Pharmaceutica N.V. Polyarylcarboxamides useful as lipid lowering agents
WO2002081460A1 (en) * 2001-04-06 2002-10-17 Janssen Pharmaceutica N.V. Lipid lowering biphenylcarboxamides
WO2003002582A1 (en) * 2001-06-27 2003-01-09 Rs Tech Corp. New chiral salen catalyst and methods for the preparation of chiral compounds from racemic epoxides by using new catalyst

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4847271A (en) 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US5041432A (en) 1987-01-30 1991-08-20 E. I. Du Pont De Nemours And Company Steroid derivatives useful as hypocholesterolemics
US5064856A (en) 1989-07-31 1991-11-12 Merck & Co., Inc. Novel hmg-coa synthase inhibitors
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
EP0618803A4 (en) 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
ATE235474T1 (de) 1992-04-20 2003-04-15 Takeda Chemical Industries Ltd 4,1-benzoxazepinderivate als squalen-synthetase inhibitoren und ihre verwendung zur behandlung von hypercholesterämie und als fungizide
AU678503B2 (en) 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
JPH10510512A (ja) 1994-10-04 1998-10-13 藤沢薬品工業株式会社 尿素誘導体とａｃａｔ阻害剤としての用途
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
AU6415998A (en) * 1997-04-18 1998-11-13 Pfizer Inc. Process and intermediates for the preparation of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (1,2,3,4-tetrahydro-isoquinolin-6-yl)-amide
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096327A1 (en) * 2000-06-01 2001-12-20 Glaxo Group Limited BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS
WO2001097810A2 (en) * 2000-06-01 2001-12-27 Glaxo Group Limited Use of therapeutic benzamide derivatives
WO2002020501A2 (en) * 2000-09-04 2002-03-14 Janssen Pharmaceutica N.V. Polyarylcarboxamides useful as lipid lowering agents
WO2002081460A1 (en) * 2001-04-06 2002-10-17 Janssen Pharmaceutica N.V. Lipid lowering biphenylcarboxamides
WO2003002582A1 (en) * 2001-06-27 2003-01-09 Rs Tech Corp. New chiral salen catalyst and methods for the preparation of chiral compounds from racemic epoxides by using new catalyst

Also Published As

Publication number Publication date
IS7622A (is) 2004-12-29
TWI342775B (en) 2011-06-01
NO20050563L (no) 2005-01-31
HRP20050103A2 (en) 2006-09-30
AU2003250215A1 (en) 2004-03-11
KR20050026483A (ko) 2005-03-15
US20060040989A1 (en) 2006-02-23
DE60319097D1 (de) 2008-03-27
MXPA05001712A (es) 2005-04-19
TW200412954A (en) 2004-08-01
DE60319097T2 (de) 2009-06-04
US20090156623A1 (en) 2009-06-18
DK1536796T3 (da) 2008-06-09
EA008061B1 (ru) 2007-02-27
IS2726B (is) 2011-03-15
US8258304B2 (en) 2012-09-04
ES2301873T3 (es) 2008-07-01
CA2494208A1 (en) 2004-03-04
PA8579901A1 (es) 2005-03-03
EP1536796A1 (en) 2005-06-08
IL166795A (en) 2010-11-30
ZA200501225B (en) 2006-07-26
CN101165052B (zh) 2012-04-18
UA79300C2 (en) 2007-06-11
SI1536796T1 (sl) 2008-08-31
CN100366252C (zh) 2008-02-06
EP1536796B1 (en) 2008-02-13
EG25699A (en) 2012-05-22
PL212405B1 (pl) 2012-09-28
CN101165052A (zh) 2008-04-23
WO2004017969A1 (en) 2004-03-04
EA200500348A1 (ru) 2005-08-25
CA2494208C (en) 2011-05-10
PT1536796E (pt) 2008-05-13
NO329308B1 (no) 2010-09-27
IL166795A0 (en) 2006-01-15
NZ538680A (en) 2006-01-27
JP4559856B2 (ja) 2010-10-13
PL373379A1 (en) 2005-08-22
KR101052204B1 (ko) 2011-07-29
ATE385796T1 (de) 2008-03-15
JP2006500371A (ja) 2006-01-05
CY1107945T1 (el) 2013-09-04
AR040968A1 (es) 2005-04-27
BR0313377A (pt) 2005-07-12
AU2003250215B2 (en) 2009-01-22
CN101165053A (zh) 2008-04-23
HK1083451A1 (en) 2006-07-07
MY136632A (en) 2008-11-28
CN1674900A (zh) 2005-09-28

Similar Documents

Publication Publication Date Title
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
HK1100559A1 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
EA200601660A1 (ru) Ингибирующие mtp арилпиперидины или пиперазины, замещенные 5-членными гетероциклами
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
UA100005C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
EA200701615A1 (ru) Новые лекарственные средства для лечения заболеваний дыхательных путей
JO2390B1 (en) Diphenylcarboxamides act as lipid-lowering agents
MXPA05010020A (es) Derivados de oxamida.
SE0303480D0 (sv) Benzofuranes
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
NO20063790L (no) Substituerte azetidin sammensetninger som cyclooxygenase-1-cyclooxygenase-2-inhibitorer, og deres fremstilling og anvendelse som medikamenter
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
UA86051C2 (en) Substituted quinoline compounds
TW200510379A (en) 1, 4-disubstituted piperidine compounds, their preparation and use as medicaments

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20170713

Year of fee payment: 15

PBON Lapse due to non-payment of renewal fee

Effective date: 20180805